TUKYSA® (tucatinib) in Combination with Antibody-Drug C

BOTHELL, Wash.--(BUSINESS WIRE)--Dec 6, 2023--

Related Keywords

United States , Canada , California , University Of Washington , Washington , Switzerland , American , Doug Maffei , Saraa Hurvitz , David Caouette , Roger Dansey , Exchange Commission , Genentech , Seagen Inc , Drug Administration , University Of Washington Department Medicine , Linkedin , American Cancer Society , Nasdaq , Roche Group , National Comprehensive Cancer Network , Lab Abnormalities , Breast Cancer Development Program , Cancer Statistics Center , Head Of The Division Hematology , Washington Department , Senior Vice President , Clinical Research Division , Fred Hutchinson Cancer , Chief Medical Officer , Confidence Interval , Hazard Ratio , Important Safety Information , Response Evaluation Criteria , Solid Tumors , Cancer Development , Positive Breast , Fetal Toxicity , Hepatic Impairment , Prescribing Information , Quarterly Report , Cancer Statistics , Accessed July , Breast Cancer , Positive Breast Cancer , Novel Treatment , Business Wire , Region ,